Insmed Announces Upcoming Presentations at European Respiratory Society 2016 International Congress

BRIDGEWATER, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported that three INS1009-related abstracts were accepted for presentation at the European Respiratory Society (ERS) 2016 International Congress taking place in Londonfrom September 3rd to 7th. INS1009 is a nebulized treprostinil prodrug, which may offer a differentiated product profile with therapeutic potential in rare pulmonary disorders such as pulmonary arterial hypertension, idiopathic pulmonary fibrosis, sarcoidosis, and severe refractory asthma.

Summarized below are the abstract titles and presentation times. The ERS abstracts are available online at the conference website at http://erscongress.org/. The ERS presentations are embargoed for release at the date/time the data are presented at the conference. Once the posters are public, they will be available on Insmed's website at http://www.insmed.com.

Session 388: Pulmonary hypertension: the clinic II
Date: Monday September 5
Session time: 12:50 - 14:40
Poster PA2398: Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution
Poster PA2403: Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009)

Session 392: Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Date: Monday September 5
Session time: 12:50 - 14:40
Poster PA2485: Inhaled INS1009 demonstrates localized pulmonary vasodilation activity

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). Insmed's earlier-stage clinical pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company believes may offer a differentiated product profile with therapeutic potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), sarcoidosis, and severe refractory asthma. To complement its internal research, Insmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information, visit www.insmed.com.

"Insmed" and "ARIKAYCE" are the company's trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.